WA-KYMETA
11.3.2024 16:01:28 CET | Business Wire | Press release
World-leading flat panel satellite antenna company Kymeta (www.kymetacorp.com) announced today leadership and board changes as the company continues to build on its innovative technology and first-to-market products. This has been an orderly collaborative process to support existing leadership retirements.
Effective April 1st, 2024, Rick Bergman will become the President and CEO of Kymeta, bringing a wealth of experience from his most recent role as Executive Vice President, Computing and Graphics at AMD. Bergman also served as President and CEO of Synaptics (SYNA) during their high growth phase from 2011 to 2019. His distinguished career includes steering organizations towards capitalizing on market opportunities with innovative technologies, leading to sustained market growth.
“Kymeta stands as a technology and market leader supported by the strength of a highly capable global team,” said Rick. “Guided by a dedication to customers, innovation, and the delivery of top-notch products, Kymeta is well-positioned for advancing global broadband communications.”
Nicole Piasecki will be appointed Chairperson of the Board, succeeding Doug Hutcheson. Nicole, who joined the board in May 2022, brings an extensive background from the aerospace and defense sector. Commenting on Rick’s appointment, Piasecki said, “I am excited about Rick joining our outstanding team. Kymeta is at the forefront of connecting the world through its hybrid communication solutions. With Rick Bergman’s track record of driving value-led growth in the technology sector bolstered by disciplined execution, we eagerly anticipate the next phase of growth for Kymeta.”
Effective March 31, 2024, Doug Hutcheson and Walter Berger are retiring from Kymeta. Throughout the last five years, their pivotal contributions have played a central role in spearheading numerous product launches and consistently fostering year-over-year growth. Their grasp of customer needs, commitment to innovation, and successful introduction of new products to the market have resulted in record-breaking achievements. They are committed to a transition of responsibilities to Rick.
Nicole added: “Our sincere gratitude goes to Doug and Walter for their unwavering commitment to Kymeta over the years. Doug and Walter have successfully laid the groundwork for Kymeta's future growth. Their departure leaves the company strategically positioned for a robust future.”
Kymeta recently completed its Series D round. These additional funds will be used for ramping up production of the recently announced Osprey™ u8 Hybrid-GEO-LEO and future product generations.
About Kymeta
Kymeta is the industry leader in flat panel satellite antennas, providing purpose-built solutions across a variety of enterprise and military applications and unlocking the commercial value of space to address the vast, unmet demand for ubiquitous broadband and truly mobile connectivity for customers around the world. Its innovative metasurface technology, coupled with a software-first approach, delivers the first commercially available, metamaterial-based and electronically steered flat panel satellite antenna. Kymeta’s low-cost, low-power, and high throughput solutions make it easy to connect on the move or while stationary – for any vehicle, vessel, aircraft, or fixed platform – enabling industries on earth to transform their operations by harnessing capacity in space.
Kymeta is a privately held company based in Redmond, Washington.
For more information, visit kymetacorp.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240311278205/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Barilla Opens Global Call for Startups Through Good Food Makers 202625.5.2026 11:47:00 CEST | Press release
The program has involved over 1,100 startups across 50+ countries, delivering 26 pilot projects. Barilla Group has opened applications for the 2026 edition of Good Food Makers, its global open innovation program designed to co-develop and test new innovative solutions with startups and innovators inside real industrial environments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521973445/en/ Since its launch in 2019, the program has involved more than 1,100 startups from over 50 countries, leading to 26 pilot projects, with over 20 projects currently active thanks to the solutions developed by the program’s alumni. This highlights the program’s role as a concrete platform for industrial scalable innovation. The 2026 edition comes at a pivotal moment for the company, following the launch of BITE (Barilla Innovation & Technology Experience), the new innovation center dedicated to developing the next generation of food prod
JEOL: Sales Launch of the Laser SEM System “LazEdge”25.5.2026 10:16:00 CEST | Press release
JEOL Ltd. (President & CEO: Izumi Oi) has developed the “LazEdge”, an SEM system equipped with a laser processing system, and begins sales on May 25, 2026. Cross-section preparation instruments such as the focused ion beam system (FIB system), are widely used in science and technology fields across research institutes, universities, and industries. In recent years, demand is increasing for a system that can process large-areas at a high speed, while achieving high-quality of the processed surface. “LazEdge” is an instrument integrating JEOL’s SEM with the laser technology proprietary of Hamamatsu Photonics K.K., and enables laser processing inside the specimen chamber of the electron microscope. This system enables high-quality cross-section specimens produced through high-speed, large-area processing to be transferred seamlessly to subsequent analyses, such as SEM observation, elemental analysis, and crystal orientation analysis, without exposure to the external environment. As a resu
TFG-001, A Novel 3D Neural Microtissue Cell Therapy, Demonstrates Superior Functionality and Reinnervation for Parkinson’s Disease25.5.2026 08:00:00 CEST | Press release
TreeFrog Therapeutics, a regenerative medicine biotech company developing next-generation cell therapies, today announced that it will present new preclinical data on TFG-001 at the 7th World Parkinson’s Conference. TFG-001, a 3D neural microtissue cell therapy, demonstrated rapid dopamine release and extensive graft-derived reinnervation across multiple advanced translational Parkinson’s disease models—supporting its potential as a best-in-class candidate. The critical need for reinnervation in Parkinson's disease In Parkinson's disease, an estimated 60–80% of dopaminergic neurons are already lost before motor symptoms even appear. The nigrostriatal pathway degenerates, destroying the essential wiring that connects dopamine-producing neurons to movement control. While chemical dopamine replacements (like levodopa) can manage symptoms, they cannot restore the spatial precision, feedback loops, or dynamic regulation of a healthy brain network. To achieve true functional restoration, it
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom